Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Petrelintide

ZUPREME

Roche · Phase 2 · Completed · Enrollment 493

NCT06662539

EudraCT 2024-512549-18

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
Petrelintide Dose 1n/rn/rn/rn/r
Petrelintide Dose 2n/rn/rn/rn/r
Petrelintide Dose 3n/rn/rn/rn/r
Petrelintide Dose 4n/rn/rn/rn/r
Petrelintide Dose 5n/rn/rn/rn/r
Placebon/rn/rn/rn/r

Not shown

  • Petrelintide Dose 1: endpoint not reported
  • Petrelintide Dose 2: endpoint not reported
  • Petrelintide Dose 3: endpoint not reported
  • Petrelintide Dose 4: endpoint not reported
  • Petrelintide Dose 5: endpoint not reported
  • Placebo: endpoint not reported